迈威生物：9MW3811注射液病理性瘢痕II期临床试验申请获批

Core Insights - The company, Maiwei Biotech, has received approval from the National Medical Products Administration for a Phase II clinical trial of its drug 9MW3811 injection for the indication of pathological scars [1] - 9MW3811 is a humanized monoclonal antibody targeting human IL-11, which has already been approved for clinical research in advanced malignancies and idiopathic pulmonary fibrosis globally [1] - The company plans to initiate the Phase II clinical trial for pathological scars by the end of 2025 [1] - Maiwei Biotech has entered into an exclusive licensing agreement with CALICO, receiving an upfront payment of $25 million, with potential milestone payments totaling up to $571 million and royalties [1]